The Comorbidity of Lung Cancer and ILD: A Review
Pneumologie · 01.03.2026 · 80 (S 01 S 01) · S52
DOI: 10.1055/s-0046-1816205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pneumologie, erschienen am 01.03.2026. Verfasst von M Uhlenbruch und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Patients with interstitial lung disease (ILD) and especially with idiopathic pulmonary fibrosis(IPF) suffer from reduced survival expectation and risk of exacerbations. Lung cancer is a relevant comorbidity in ILD patients and associated with impaired survival.The most frequent ILD among patients with NSCLC (Non-small cell lung cancer) is idiopathic pulmonary fibrosis (IPF), which is associated with an greater decline in lung function and a higher risk of death.The prevalence of lung cancer in patients with ILD is up to 10% and in autopsy studies a prevalence up to 48% has been found.There are no guidelines for patients with lung cancer and ILD. Moreover, no adequate evidence is available.Therefore, we reviewed currently available literature to present an overview of the state of the art.In this review we focus on staging and treatment of the comorbidity of lung cancer and ILD. Publication History Article published online: 04 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Uhlenbruch, M., Polke, M., Eiff, D. V., Koryllos, A., & Krüger, S. (2026). The Comorbidity of Lung Cancer and ILD: A Review. Pneumologie, 80(S 01 S 01), S52. https://doi.org/10.1055/s-0046-1816205
Vancouver
Uhlenbruch M, Polke M, Eiff DV, Koryllos A, Krüger S. The Comorbidity of Lung Cancer and ILD: A Review. Pneumologie. 2026;80(S 01 S 01):S52. doi:10.1055/s-0046-1816205
BibTeX
@article{Uhlenbruch2026,
author = {Uhlenbruch, M and Polke, M and Eiff, D von and Koryllos, A and Krüger, S},
title = {The Comorbidity of Lung Cancer and ILD: A Review},
journal = {Pneumologie},
year = {2026},
volume = {80},
number = {S 01 S 01},
pages = {S52},
doi = {10.1055/s-0046-1816205}
}
EUVIMED